Trials / Completed
CompletedNCT02890173
Study of CS-3150 in Patients With Essential Hypertension
A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,001 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.
Detailed description
Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg compared to Eplerenone in patients with essential hypertension. Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg compared to 2.5 mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-3150 | |
| DRUG | Eplerenone |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-07-11
- Completion
- 2017-07-11
- First posted
- 2016-09-07
- Last updated
- 2018-12-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02890173. Inclusion in this directory is not an endorsement.